Has Joseph Thibodeau, MD received payments from drug or device companies?

Yes. Drug and device makers reported $251,307 in general payments to Joseph Thibodeau, MD across 1,048 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Thibodeau, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Thibodeau, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Thibodeau, MD

Cardiovascular Disease · Omaha, NENPI 1316973381

Payments from drug & device makers

$251,307in general payments, 2019–2025

Across 1,048 payments — averaging $239.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim Pharma GmbH & Co.kg$71K
Novo Nordisk AS$69K
Boehringer Ingelheim International GmbH$36K
AstraZeneca$32K
Novartis$23K
Medtronic$8K
plus $11K from 41 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim Pharma GmbH & Co.kg	15	$70,652
Novo Nordisk AS	236	$69,330
Boehringer Ingelheim International GmbH	88	$36,250
AstraZeneca	68	$32,253
Novartis	141	$23,424
Medtronic(2 entities)	123	$8,232
Boston Scientific	22	$1,319
Pfizer	71	$1,226
E.r. Squibb & Sons, L.L.C.	50	$1,126
Edwards Lifesciences	12	$1,027
Abbott	10	$990
Boehringer Ingelheim	43	$869
Amgen	35	$541
Shockwave Medical, Inc	8	$419
Esperion Therapeutics, Inc.	14	$397
Siemens Medical Solutions USA, Inc.	2	$341
ZOLL Respicardia, Inc.	3	$293
Philips North America LLC	5	$275
Johnson & Johnson	15	$231
Atricure, Inc.	2	$197
Amarin Pharma, Inc.	11	$187
Novo Nordisk	9	$179
Daxor Corporation	3	$170
Heartflow, Inc.	2	$155
Sanofi-aventis U.S. LLC	9	$141
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	9	$130
Bridgebio Pharma, Inc.	4	$129
Lundbeck LLC	3	$122
Impulse Dynamics (USA) Inc.	2	$113
Merck	7	$111
Regeneron Healthcare Solutions, Inc.	3	$47
Chiesi USA, Inc.	3	$47
Abiomed	2	$42
Scpharmaceuticals Inc.	2	$39
Cardiva Medical, Inc.	1	$36
Actelion Pharmaceuticals US, Inc.	2	$34
Biosense Webster, Inc.	2	$30
Lexicon Pharmaceuticals, Inc.	2	$30
Cardiovascular Systems Inc.	1	$24
Teleflex LLC	1	$24
Alnylam Pharmaceuticals Inc.	1	$24
Kiniksa Pharmaceuticals International, PLC	1	$20
Lantheus Medical Imaging, Inc.	1	$19
Kowa Pharmaceuticals America, Inc.	1	$18
Baxter Healthcare	1	$15
Vifor Pharma, Inc.	1	$14
Cvrx, Inc.	1	$12

How this compares

$251,307 in reported general payments places this provider in the 90th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska →

Medicare billing

Part B allowed, 2024

$256,835

Medicare patients

2,548

Services billed

6,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Omaha

Ronald ZoltyOmaha$6.3M
Jeffrey CarstensOmaha$299K
Edward OlearyOmaha$104K
Michael PetersOmaha$90K
John HenryOmaha$82K
Amjad KabachOmaha$75K
Thomas PorterOmaha$64K
Stanislaw SojkaOmaha$60K
Qais RadaidehOmaha$50K
Mark HolmbergOmaha$31K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →